Vir’s VIR-2482 Flunks In Phase II As Company Shifts Focus To Other Programs

 
• By Alaric DeArment
Vir said its trial of VIR-2482 in influenza A prevention was unsuccessful • Source: Shutterstock

More from Clinical Trials

More from R&D